IHU RespirERA strengthens its leadership in medical innovation by launching the world’s first international training program in liquid biopsy for pathologists.
Staying true to its mission of accelerating access to cutting-edge technologies in respiratory health, IHU RespirERA has launched an unprecedented training module in liquid biopsy in Nice, as part of the European Master in Molecular Pathology (EMMP) directed by Professor Marius Ilié, Deputy Director of the IHU RespirERA. This initiative is the first of its kind worldwide.
This unique training module, led by international experts such as Professors Paul Hofman (Director of IHU RespirERA) and Klaus Pantel (a pioneer in liquid biopsy), addresses a crucial challenge: ensuring that all patients, regardless of where they are treated or their social background, have access to the latest diagnostic innovations.
“No other training of this kind exists today. Yet it is essential to ensure that every patient, wherever they are treated, can benefit from this major breakthrough,” emphasizes Professor Paul Hofman.
Liquid biopsies, performed using a simple blood sample, can detect circulating tumor DNA or other biomarkers released by tumors. These innovative tools pave the way for more refined cancer monitoring, by identifying mutations, detecting early relapses, or adjusting treatments in real time.
However, their use remains limited, often confined to clinical trials. In France, for instance, these analyses are not yet systematically included in routine care outside major hospital centers. This observation fully supports IHU RespirERA’s initiative: promoting a shared culture among biologists, pathologists, and clinicians, with improved coordination around the same samples.
This first module brought together more than 40 professionals from 19 countries, marking a major step forward in expanding access to innovation for the benefit of all patients.
Read the full Nice-Matin article here: full article
